Home » Science » Foster your Research with Free Molecules or an Industrial Postdoc Grant from Boehringer Ingelheim
Foster your Research with Free Molecules or an Industrial Postdoc Grant from Boehringer Ingelheim
Posted on 12.09.2023
With 53,000 employees worldwide, Boehringer Ingelheim is a leading global pharmaceutical company that aims to develop novel treatments and technologies. Boehringer Ingelheim invites talented early-career researchers to solve pre-defined scientific questions with innovative solutions for the benefit of patients.
Member of the DDEA Advisory Board, Nicolas Dumoulin, is Head of Corporate Strategy & Development at Boehringer Ingelheim based at the headquarters in Ingelheim, Germany, and encourages members of the DDEA network to file applications.
Industrial Postdoc Grant: Advanced Cellular Models for Retinal Diseases
Visual impairment and blindness have a profound and devastating impact on the lives of the affected person, their families and society. Age-related macular degeneration (AMD) is a leading cause of blindness worldwide, affecting more than 200 million people. In addition, more than 100 million people are affected worldwide by diabetic retinopathies.
The current research question goes like this:
Using innovative cellular systems, how would you propose to explore the multifactorial pathophysiology of retinal diseases with the goal to identify and explore novel therapeutic entry points for patients in need?
– As diabetes is a key driver of several retinal diseases, we welcome applications with innovative solutions from talented early-career researchers within the DDEA network. The models proposed should help to bridge the gap between laboratory research and clinical applications, says Nicolas Dumoulin.
Read more and apply throughopn2TALENTS. Submission deadline: 25 October 2023
Foster your Research with Free Molecules
Boehringer Ingelheim not only offers funding for postdoctoral researchers. The company has also created the open science portal called opnMe. The aim is to foster scientific collaboration, and, as something unique, Boehringer Ingelheim offers molecules or biologics shipped for free for research.
This makes it a fine match with the strategic initiatives of DDEA, encompassing networking and collaborations across research fields, sectors and borders.
– At Boehringer Ingelheim, we are prepared to share high-quality pharmacological probes coming out of our own research. We want to foster disease biology investigation and research on potential drug candidates. The DDEA is a platform for knowledge sharing and has the network of talented researchers. In my role as member of the DDEA Advisory Board and Head of Strategy & Development at Boehringer Ingelheim, I wish to contribute to bridging the two, says Nicolas Dumoulin.
Odense University Hospital
Entrance 93, 8th floor
DK-5000 Odense C
+45 2964 6764